The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological features and response to platinum-based chemotherapy (PBC) in pancreatic neuroendocrine carcinoma (pNEC): Updated results of Japan pNEC study.
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Lilly; Novartis; OncoTherapy Science; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Eisai (Inst); Merck Serono (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Waki Hosoda
No Relationships to Disclose
 
Keitaro Matsuo
No Relationships to Disclose
 
Makoto Ueno
Honoraria - Abbott Japan; AstraZeneca; Boston Scientific; Kyowa Hakko Kirin; Lilly; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Masayuki Furukawa
No Relationships to Disclose
 
Hideyuki Yoshitomi
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Guerbet; Kowa; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Noritoshi Kobayashi
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai (Inst)
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer Yakuhin; Daiichi Sankyo; Hospira; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Daiichi Sankyo; Torii Pharmaceutical
 
Yuzo Kodama
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - Lilly; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Yakult Honsha
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Yakult Honsha (Inst)
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Kei Yane
No Relationships to Disclose
 
Yoshiaki Tsuchiya
No Relationships to Disclose
 
Kenji Notohara
No Relationships to Disclose
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sawai Pharmaceutical Co; Shionogi; Sumitomo Group; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Yasushi Yatabe
No Relationships to Disclose
 
Susumu Hijioka
Honoraria - Eisai; Nobelpharma; Novartis; Pfizer; Takeda
Research Funding - Teijin Pharma (Inst)